Importantly, since compounds inducing TOP1-mediated DPCs are currently used in cancer treatment [46–48], understanding the underlying mechanism of the repair pathway is essential for improving the efficiency of combination therapy with TDP1 and MUS81 inhibitors. Here, MUS81 is linked to cancer.